Recently, a biopharmaceutical company completed at 36 week Phase IV study of 175 patients across 40 trial sites to evaluate the effectiveness and safety of a recently approved anti-seizure medication as adjunctive therapy in focal seizure. Patient retention was the primary efficacy endpoint and seizure frequency was a secondary efficacy endpoint. The study also looked at tolerability. The initial study results showed that a substantial number of patients remained on therapy and experienced reduced seizure frequency. Read the available case study to find out more.